To see the results of Itraconazole tablets in operated patients of Allergic Fungal Rhinosinositis.

Not yet recruiting

• Conditions: Acute sinusitis, unspecified,

• Registration Number: CTRI/2022/04/042152
• Lead Sponsor: All India Institute of Medical Sciences Jodhpur

Brief Summary

This is a double blinded Randomised , placebo controlled , parellel study to evaluate whether post operative itraconazole for 3 weeks prevents recurrence of the disease  till 6 months in patients of Allergic Fungal Rhinosinusitis . The details of data shall be collected by way of Endoscopic and Radiologic systems.

Detailed Description

Not available

Study Timeline

• Study Start: 2022-01-05
• Last Update Posted: 2022-04-20

Recruitment & Eligibility

• Status: Not Yet Recruiting
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

• 1.Adult patients with Allergic fungal rhino-sinusitis undergoing FESS 2.
• Previously operated cases of chronic allergic rhino-sinusitis undergoing Revision FESS.

Exclusion Criteria

• 1.Patients with a previous history of sensitivity to Itraconazole 2.Patients who have received post-operative steroids.
• 3.Patient on immunosuppressive drugs or diagnosis of immunodeficiency disease 4.Patients previously treated with post-operative Itraconazole.
• 5.Pregnancy.
• 6.Patients having hepatic dysfunction 7.Patients <18 years of age.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Recurrence of Allergic fungal rhinosinusitis	6 months post operatively

Secondary Outcome Measures

Name	Time	Method
To compare the outcomes using scoring systems	such as SNOT-22, DIPS score, Lund Kennedy

Trial Locations

Locations (1)

AIIMS , JODHPUR; 🇮🇳 Jodhpur, RAJASTHAN, India

AIIMS , JODHPUR

🇮🇳Jodhpur, RAJASTHAN, India

Dr Sristi Suman

Principal investigator

9065498468

sristisuman19@gmail.com